. "Immunogenicity of human papilomavirus vaccines"@en . "Imunogenita vakc\u00EDn proti lidsk\u00E9mu papilomaviru" . "1"^^ . . "371741" . "1"^^ . . . "2" . "The uniqueness of the first really anti-cancer human papilomavirus vaccine (HPV) has started higher interest in vaccination not only among pediatricians and epidemiologists, but also among gynecologists, infectologists and general practitioners for adults. It lies in a significantly higher immunity response to HPV vaccination than to natural HPV infection. With regard to the fact that the most important role in HPV protection is played by serum virus neutralizing antibodies, the vaccine immunogenicity, high production of IgG antibodies and length of their persistence are crucial for the high efficiency of HPV vaccination. Two recombinant HPV vaccines, the bivalent Cervarix and quadrivalent Silgard (or Gardasil), are currently available in Europe. These vaccines differ in the number and amount of antigenes, production system used for the production of antigenes, adjuvant system and indication range. The accessible data from a long-time monitoring enable to evaluate the rapidity of decline of serum a"@en . "Imunogenita vakc\u00EDn proti lidsk\u00E9mu papilomaviru"@cs . "RIV/60162694:G44__/08:00002079!RIV09-MO0-G44_____" . "Imunogenita vakc\u00EDn proti lidsk\u00E9mu papilomaviru" . . . "Chl\u00EDbek, Roman" . "Immunogenicity of human papilomavirus vaccines"@en . "9"^^ . . . "HPV infection; immunogenicity; papilomavirus; serum antibodies; transudation."@en . . "1802-3150" . . . "Jedine\u010Dnost prvn\u00ED skute\u010Dn\u011B protin\u00E1dorov\u00E9 vakc\u00EDny proti lidsk\u00E9mu papilomaviru (HPV) odstartovala je\u0161t\u011B vy\u0161\u0161\u00ED z\u00E1jem o o\u010Dkov\u00E1n\u00ED nejenom mezi pediatry, epidemiology, ale i mezi gynekology, infektology a praktick\u00FDmi l\u00E9ka\u0159i pro dosp\u011Bl\u00E9. Unik\u00E1tnost vakc\u00EDny spo\u010D\u00EDv\u00E1 ve v\u00FDrazn\u011B vy\u0161\u0161\u00ED imunitn\u00ED odpov\u011Bdi na HPV vakcinaci ne\u017E na p\u0159irozenou HPV infekci. Vzhledem k tomu, \u017Ee nejv\u00FDznamn\u011Bj\u0161\u00ED \u00FAlohu v HPV protekci hraj\u00ED s\u00E9rov\u00E9 virus neutraliza\u010Dn\u00ED protil\u00E1tky, je imunogenita vakc\u00EDny, vysok\u00E1 produkce IgG protil\u00E1tek a d\u00E9lka jejich p\u0159etrv\u00E1v\u00E1n\u00ED kl\u00ED\u010Dovou pro vysokou \u00FA\u010Dinnost HPV vakcinace. V sou\u010Dasn\u00E9 dob\u011B jsou v Evrop\u011B dostupn\u00E9 dv\u011B rekombinantn\u00ED HPV vakc\u00EDny, bivalentn\u00ED Cervarix a kvadrivalentn\u00ED Silgard (resp. Gardasil). Ob\u011B vakc\u00EDny se li\u0161\u00ED v po\u010Dtu a mno\u017Estv\u00ED antigen\u016F, v produk\u010Dn\u00EDm syst\u00E9mu pou\u017Eit\u00FDm na p\u0159\u00EDpravu antigen\u016F, v adjuvantn\u00EDm syst\u00E9mu a v indika\u010Dn\u00EDm rozsahu. Dostupn\u00E1 data z dlouhodob\u00E9ho sledov\u00E1n\u00ED dovoluj\u00ED hodnotit rychlost poklesu s\u00E9rov\u00FDch protil\u00E1tek a hodnoty s\u00E9roprotekce u obou vakc\u00EDn pro jednotliv\u00E9 c\u00EDlov\u00E9 typy HPV. P\u0159e"@cs . . "Imunogenita vakc\u00EDn proti lidsk\u00E9mu papilomaviru"@cs . "4" . . "RIV/60162694:G44__/08:00002079" . . "Vakcinologie" . "Jedine\u010Dnost prvn\u00ED skute\u010Dn\u011B protin\u00E1dorov\u00E9 vakc\u00EDny proti lidsk\u00E9mu papilomaviru (HPV) odstartovala je\u0161t\u011B vy\u0161\u0161\u00ED z\u00E1jem o o\u010Dkov\u00E1n\u00ED nejenom mezi pediatry, epidemiology, ale i mezi gynekology, infektology a praktick\u00FDmi l\u00E9ka\u0159i pro dosp\u011Bl\u00E9. Unik\u00E1tnost vakc\u00EDny spo\u010D\u00EDv\u00E1 ve v\u00FDrazn\u011B vy\u0161\u0161\u00ED imunitn\u00ED odpov\u011Bdi na HPV vakcinaci ne\u017E na p\u0159irozenou HPV infekci. Vzhledem k tomu, \u017Ee nejv\u00FDznamn\u011Bj\u0161\u00ED \u00FAlohu v HPV protekci hraj\u00ED s\u00E9rov\u00E9 virus neutraliza\u010Dn\u00ED protil\u00E1tky, je imunogenita vakc\u00EDny, vysok\u00E1 produkce IgG protil\u00E1tek a d\u00E9lka jejich p\u0159etrv\u00E1v\u00E1n\u00ED kl\u00ED\u010Dovou pro vysokou \u00FA\u010Dinnost HPV vakcinace. V sou\u010Dasn\u00E9 dob\u011B jsou v Evrop\u011B dostupn\u00E9 dv\u011B rekombinantn\u00ED HPV vakc\u00EDny, bivalentn\u00ED Cervarix a kvadrivalentn\u00ED Silgard (resp. Gardasil). Ob\u011B vakc\u00EDny se li\u0161\u00ED v po\u010Dtu a mno\u017Estv\u00ED antigen\u016F, v produk\u010Dn\u00EDm syst\u00E9mu pou\u017Eit\u00FDm na p\u0159\u00EDpravu antigen\u016F, v adjuvantn\u00EDm syst\u00E9mu a v indika\u010Dn\u00EDm rozsahu. Dostupn\u00E1 data z dlouhodob\u00E9ho sledov\u00E1n\u00ED dovoluj\u00ED hodnotit rychlost poklesu s\u00E9rov\u00FDch protil\u00E1tek a hodnoty s\u00E9roprotekce u obou vakc\u00EDn pro jednotliv\u00E9 c\u00EDlov\u00E9 typy HPV. P\u0159e" . "Z(MO0FVZ0000502)" . "[73AAB2DFB03A]" . . "CZ - \u010Cesk\u00E1 republika" . "G44" . . .